Aranda Richard 4

What Happened
Richard Aranda, Chief Medical Officer of Gossamer Bio (GOSS), had a group of outstanding stock options cancelled and simultaneously regranted (derivative transactions) as part of a one‑time option repricing effective March 19, 2026. The filing shows dispositions to the issuer totaling 2,348,118 option shares and corresponding grants of 2,348,118 repriced options. The new per‑share exercise price for the repriced options is $0.45. No cash purchase or open‑market sale of common stock is reported in this filing.

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 20, 2026 (timely).
• Total options affected: 2,348,118 (sum of multiple dispositions and matching grants).
• New exercise price after repricing: $0.45 per share (per footnote).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 — one‑time repricing reduced exercise price to $0.45; all other terms (including vesting and term) remain in effect. F2 — the regranted options vest per the original award agreements and require continued service to vest.
• Transaction type: Derivative repricing (codes D = disposition to issuer; A = grant/acquisition of derivative), not a cash sale/purchase.

Context

• This was an internal option repricing/regrant (administrative adjustment), not an open‑market buy or sale of common stock. Repricings are typically intended to adjust incentive compensation and do not by themselves indicate insider buying or selling of shares.